

RESPONSE TO NOTICE TO COMPLY  
Application No. 10/758,562

MSCV-puro BPV1E2 for producing the E2 recombinant from BPV. The retrovirus vector pCMSVpuro comprises a puromycin resistance gene as a selection marker.

Please delete the paragraph on page 85, line 19, to page 86, line 6 and replace it with the following paragraph:

Human epidermal cells HDK1 (BioWhittaker) were infected with the retroviruses LXS-16E6, LXS-16E7 and LXS-16E6E7 for producing HPV 16 derived E6 or E7 recombinants, respectively. As a negative control, a human epidermal cell HDK1 infected with a retrovirus vector pCLXS-16E6 was used. A cell line in which continued infection of the retrovirus vector was established was selected by culturing the cells on a medium containing G418 at 50 µg/mL for 3 days. After infection, expression of the hWAPL gene induced by a recombinant protein of the E6 or E7 from HPV 16 was determined by Western blotting using a specific antibody recognizing a region of partial amino acid sequence 50 to 66 (amino acid sequence: CNFKPDIQEIPKKPKVEE (SEQ ID NO: 20)) in the oncogenic protein hWAPL (FIG. 6).

Please delete the paragraph on page 87, lines 11-18 and replace it with the following paragraph:

A promoter of hWAPL gene was amplified and isolated by PCR method using a genomic DNA in DLD-1 cell as a template with use of a pair of primers:

primer 1

(sequence: GTGCATCCCACCCACAGTGGGAAGACATGG)(SEQ ID NO: 21) and

primer 2

(sequence: CCGCTTCCGCCGGTGAATGGTCAGTGCTGG) (SEQ ID NO: 22).

Please delete the paragraph on page <sup>89</sup>~~88~~, lines <sup>17-24</sup>~~11-18~~ and replace it with the following paragraph:

259  
12/27/07